Borenius advised Sooma Medical on a EUR 5 million growth funding round

We advised Sooma Oy and its founders on the company’s latest growth funding round, in which Sooma secured EUR 5 million to accelerate product development and expand its global reach.

Based in Helsinki, Finland, Sooma Oy is a pioneer in non-invasive brain stimulation devices for the treatment of psychiatric and neurological disorders. Sooma is committed to improving access to depression treatment worldwide and offers a unique, drug-free solution with its Transcranial Direct Current Stimulation (tDCS) therapy. This innovative treatment, which can be self-administered at home, has been proven effective in placebo-controlled trials and is designed to alleviate depression symptoms without the systemic side effects associated with traditional medications.

The funding round was led by Nordic early-stage investor Voima Ventures, known for backing science-based solutions, and included contributions from the Singapore-based Verge HealthTech Fund and Helsinki-based family office Stephen Industries. The investment will support Sooma’s mission to provide hope and efficient care to those facing mental health challenges, particularly those underserved by medication or with limited access to psychotherapy.

Read more here.